Syntimmune
Latest round
- Series B
Last raised
- Jun 2017
Total raised
- $76M
Investors
- 4
About Syntimmune
Syntimmune, Inc.Founded in 2013 and headquartered in Boston, US, Syntimmune, Inc. specializes in developing therapies for complement-mediated disorders. In September 2018, it was acquired by Alexion Pharmaceuticals, Inc.2 bn.Syntimmune, Inc. focuses on developing innovative therapies for patients with complement-mediated disorders, particularly through monoclonal antibodies.Syntimmune, Inc. generates revenue through the development of its therapeutic products, particularly those related to complement-mediated diseases.With the acquisition by Alexion Pharmaceuticals, Syntimmune, Inc. is positioned to leverage Alexion's infrastructure for broader market penetration. Upcoming initiatives include the development of new products that expand treatment options for patients with rare diseases. Alexion plans to utilize Syntimmune's expertise to explore new markets, particularly in Europe and Asia by 2021, addressing the unmet medical needs in these regions.
Who invested in Syntimmune
4 investors across 4 rounds
See all investors in Syntimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Syntimmune
Who invested in Syntimmune?
Syntimmune has 4 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Syntimmune raised?
Syntimmune has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Syntimmune last raise money?
Syntimmune's most recent round on record is a Series B, in Jun 2017.
What does Syntimmune do?
Syntimmune is a biotechnology company.
Where is Syntimmune headquartered?
Syntimmune is headquartered in Boston, US.
Which VCs invest in companies like Syntimmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Syntimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Syntimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.